Brief: KORU Medical Systems Q2 Gross Margin 63.5%

Koru Medical Systems

06/08/2025 21:05

Overview

KORU Medical Q2 2025 net revenues rise 21% to $10.2 mln

Gross margin drops to 63.5% on favourable year-ago inventory adjustment, current qtr tariff charges

Adjusted EBITDA turns positive

Outlook

Company raises 2025 revenue guidance to $39.5 - $40.5 mln

KORU Medical reiterates full-year gross margin guidance of 61% - 63%

Company expects positive cash flow from operations for full year 2025

KORU Medical forecasts ending cash balance greater than $8.1 mln for 2025

Result Drivers

DOMESTIC REVENUE GROWTH - Driven by higher consumable volumes and market share gains from new and existing accounts

INTERNATIONAL REVENUE GROWTH - Boosted by higher consumable and pump volumes, prefill patient conversions, and expansion into new markets

PHARMA SERVICES GROWTH - Increased revenues from product sales for clinical trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$200,000
Q2 Gross Margin
63.5%
Q2 Operating Expenses
$6.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for KORU Medical Systems Inc is $6.00, about 45.3% above its August 5 closing price of $3.28

Press Release: ID:nBw5LjJ7la

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)